Meeting
2019 ASCO Annual Meeting
A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
Authors
Timothy A Yap
The University of Texas MD Anderson Cancer Center, Houston, TX
Timothy A Yap , Kyriakos P. Papadopoulos , Patricia LoRusso , Deborah J.L. Wong , Siwen Hu-Lieskovan , Josefin-Beate Holz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03440437
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2652)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2652
Abstract #
TPS2652
Poster Bd #
292a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward
Poster
2021 ASCO Annual Meeting
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
First Author: Thorsten Oliver Goetze
Poster
2015 ASCO Annual Meeting
A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
First Author: Patrick Alexander Ott